“Flu Drugs Expensive and More Evidence Needed

Return to Vaccination News Home Page

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.

Although Roche's Tamiflu and GlaxoSmithKline's Relenza--two neuraminidase inhibitors which work by blocking the action of viral enzymes--reduced the likelihood of contracting influenza, researchers are demanding further studies to prove that the drugs are effective in preventing the illness in high-risk groups, such as children and seniors. Researchers report in the British Medical Journal that the drugs reduced the risk of contracting the flu by 70 percent to 90 percent. However in a commentary accompanying the study, Klaus Stohr, the project leader of the World Health Organization Influenza Program, asserts that annual influenza shots are the best defense against the illness, noting that neuraminidase inhibitors can complement the vaccine. Stohr notes that the drugs are expensive, costing almost $40 in Britain for a single course of treatment, and he contends that the lack of efficacy information for the drugs in the groups most affected by the flu limits their use.

Return to Vaccination News Home Page

DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.